SMART DEVICE FOR EARLY DETECTION OF APOPLEXY

V. Sanjay Srinivas
B. Tech Biomedical Engineering
Bharath Institute of Higher Education and Research

S. Sriram
B. Tech Biomedical Engineering
Bharath Institute of Higher Education and Research

Ms. V. Kaviya
Assistant Professor
Bharath Institute of Higher Education and Research

ABSTRACT**—** *Apoplexy is a leading cause of disabilities in adults and the elderly which can result in numerous social or economic difficulties. If left untreated, stroke can lead to death. In most cases, patients with stroke have been observed to have abnormal bio-signals (i.e., ECG). Therefore, if individuals are monitored and have their bio-signals measured and accurately assessed in real-time, they can receive appropriate treatment quickly. In this paper, we developed a stroke prediction system that detects stroke using real-time bio-signals. Both machine learning (Random Forest) and deep learning (Long Short-Term Memory) algorithms were used in our system. EMG (Electromyography) bio-signals were collected in real time from thighs and calves, after which the important features were extracted, and prediction models were developed based on everyday activities. Prediction accuracies of 90.38% for Random Forest and of 98.958% for LSTM were obtained for our proposed system. This system can be considered an alternative, low-cost, real-time diagnosis system that can obtain accurate stroke prediction and can potentially be used for other diseases such as heart disease.*

KEYWORDS: *- Electromyography, apoplexy diseases analysis, machine learning.*

I. INTRODUCTION

Stroke remains one of the most significant health challenges globally, causing substantial morbidity, mortality, and socioeconomic burdens. It is a leading cause of long-term disability in adults and the elderly, often resulting in profound physical, cognitive, and emotional impairments. Despite advances in medical science and technology, the management of stroke continues to pose substantial challenges, particularly in timely diagnosis and intervention.

1. Stroke: A Global Health Crisis

Stroke, often referred to as a "brain attack," occurs when blood flow to a part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. This interruption can be due to a blockage in the blood vessels (ischemic stroke) or the rupture of a blood vessel (hemorrhagic stroke). The consequences of stroke can be devastating, leading to permanent disabilities or even death. According to the World Health Organization (WHO), stroke is the second leading cause of death worldwide and a significant cause of long-term disability, with an estimated 6.2 million deaths attributed to stroke each year.

2. The Impact of Stroke on Individuals and Society

The impact of stroke extends beyond the individual, affecting families, caregivers, and society at large. Survivors often face challenges in performing daily activities, maintaining independence, and participating in social and economic life. Physical disabilities, such as paralysis or weakness on one side of the body (hemiparesis), speech and language impairments, and cognitive deficits, significantly impact quality of life and functional independence. Stroke survivors may also experience psychological issues, including depression, anxiety, and post-traumatic stress disorder (PTSD), further complicating their recovery and rehabilitation.

3. Challenges in Stroke Diagnosis and Management

Despite the development of clinical guidelines and protocols for stroke management, timely diagnosis and intervention remain challenging. The window for administering clot-busting medication, such as tissue plasminogen activator (tPA), is narrow, typically within the first few hours after symptom onset. However, many stroke patients do not arrive at the hospital within this critical time window, delaying treatment and potentially exacerbating brain damage. Moreover, misdiagnosis or delayed diagnosis of stroke symptoms, particularly in atypical or mild cases, can lead to inappropriate management and poorer outcomes.

4. The Role of Technology in Stroke Care

Advances in medical technology have revolutionized the diagnosis, treatment, and rehabilitation of stroke patients. Imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), play a crucial role in diagnosing stroke, identifying the type and location of brain lesions, and guiding treatment decisions.

Telemedicine and telestroke programs enable remote consultation and assessment of stroke patients, facilitating timely access to specialized care, especially in underserved or rural areas. Additionally, wearable devices and mobile health (mHealth) applications offer opportunities for remote monitoring of stroke survivors, promoting self-managemzent and early detection of recurrent events.

5. The Promise of Bio-Signal Analysis in Stroke Prediction

Bio-signals, such as electromyography (EMG), electroencephalography (EEG), and electrocardiography (ECG), provide valuable insights into the physiological processes underlying stroke and other neurological disorders. By monitoring bio-signals in real-time, researchers and clinicians can detect subtle changes associated with stroke onset and progression, facilitating early intervention and personalized treatment strategies.

EMG, which measures the electrical activity of muscles, offers a non-invasive and accessible means of assessing motor function and detecting abnormalities in muscle activation patterns. Recent advancements in signal processing techniques and machine learning algorithms have enabled the development of predictive models that leverage EMG data for stroke prediction with high accuracy and reliability.

In this, we present a novel approach to stroke prediction using real-time EMG bio-signals. Our research focuses on the development of a low-cost, portable, and user-friendly system capable of detecting stroke onset in the early stages, facilitating prompt intervention and improving patient outcomes. By combining machine learning and deep learning algorithms, namely Random Forest and Long Short-Term Memory (LSTM), we aim to achieve high prediction accuracy and robust performance across diverse patient populations. Through rigorous experimentation and validation, we demonstrate the feasibility and efficacy of our proposed stroke prediction system, paving the way for future advancements in stroke care and management.

II. RELEVANT STUDIES

Andrea Nathalie et al (2020) proposed the prospective, multicenter SMART SF trial demonstrated the acute safety and effectiveness of the 56-hole porous tip irrigated contact force (CF) catheter for drug-refractory paroxysmal atrial fibrillation (PAF) ablation with a low primary adverse event rate (2.5%), leading to FDA approval of the catheter. Here, we are reporting the long-term effectiveness and safety results that have not yet been reported.[1]

Padmaloshani et al (2020) highlighted Paroxysm is a very fatal condition convulsion could be a terribly fatal condition that is caused as a result of imbalance within the system nervous. The quite common symptoms of convulsion embrace sudden fluctuations in heart beat rate and involuntary muscular movements (seizures). The aura (practical symptom) of brain disease includes fluctuations in heartbeat, nausea, symptom etc. sudden prevalence throughout sleeping hours will even result in the patient's death, if no immediate, correct attention is provided by a looker or a doctor. With the help of this technique, the patient will lead a traditional life. The electronic system given here could be a wearable device that predicts the prevalence of convulsion in a very couple of minutes advance. The device utilizes the signals from form to find the prevalence of brain disease. As presently because the device detects the symptoms, it transmits a coded signal. The signal is decoded by a wireless receiver to provide management signals for change associate alarm device; mobile electronic communication device associated an automatic vehicle system.[2]

David Dunker et al (2021) analyzed the possibilities and implementation of wearable cardiac monitoring beyond atrial fibrillation are increasing continuously. This review focuses on the real-world use and evolution of these devices for other arrhythmias, cardiovascular diseases and some of their risk factors beyond atrial fibrillation. The management of notarial fibrillation arrhythmias represents a broad field of wearable technologies in cardiology using Holder, event recorder, electrocardiogram (ECG) patches, wristbands and textiles. Implementation in other patient cohorts, such as ST-elevation myocardial infarction (STEMI), heart failure or sleep apnea, is feasible and expanding. In addition to appropriate accuracy, clinical studies must address the validation of clinical pathways including the appropriate device and clinical decisions resulting from the surrogate assessed.[3]

Yutan Gout et al (2021) subjected A primary ML-based prediction model of AF onset (M1) was developed on the basis of the Huawei Heart Study, a general-population AF screening study using photoplethysmography (PPG)–based smart devices. After optimization in 554 individuals with 469,267 PPG data sets, the optimized ML-based model (M2) was further prospectively validated in 50 individuals with paroxysmal AF at high risk of AF onset, and compared with 72-hour Holter electrocardiographic (ECG) monitoring, a criterion standard.[4]

Constanze Schmidt et al (2020**)** presented the early recognition of paroxysmal atrial fibrillation (pAF) is a major clinical challenge for preventing thromboembolic events. In this prospective and multicenter study, we evaluated prediction scores for the presence of pAF, calculated from non-invasive medical history and echocardiographic parameters, in patients with unknown AF status.[5]

Larry A Chinitz et al (2018) explained the prospective, open-label, non-randomized SMART-SF was conducted at 17 US sites. Circumferential pulmonary vein (PV) isolation was performed with confirmation of entrance block in all PVs. Stable ablation sites were identified using CARTO VISITAG™ Module. Primary adverse events, periprocedural AEs within 30 days of ablation procedure, acute effectiveness (confirmation of entrance block for targeted PVs), CF, and procedural parameters were assessed. Overall, 165 patients were enrolled (mean age, 62.7 years; male, 57.9%; white, 97%; left ventricular ejection fraction, 60.1 ± 7%; left atrium diameter, 38.8 ± 6 mm); 159 underwent radiofrequency ablation and comprised the safety cohort. Primary safety performance criteria were met: primary AE rate was 2.5% (4/159; cardiac tamponade [n = 2], thrombo-embolism [n = 1], transient ischaemic attack [n = 1]). All primary AEs resolved/improved within the 1-month follow-up period. Acute procedural effectiveness was attained in 96.2% (95% confidence interval: 92.0–98.6%) of patients. Procedure time, fluoroscopy time, and fluid delivered were observed in comparison to predecessor catheters.[6]

Panel Simon Buatois et al (2017) projected the paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder characterized by intravascular hemolytic anemia and hemoglobinuria. Lactate dehydrogenase (LDH) is a cytoplasmic enzyme that is abundant in red blood cells. Serum LDH level is used as a biomarker for intravascular hemolysis to monitor response to PNH treatment. Crovalimab is a novel antihuman C5 antibody engineered with Sequential Monoclonal Antibody Recycling Technology that is being evaluated as a therapy for PNH in the 4-part, dose-optimization. Which includes healthy volunteers and patients with PNH who received or did not receive prior C5 inhibition therapy with eculizumab. In this study, COMPOSER data were used to obtain a dose-concentration effect relationship between crovalimab and LDH through development of a pharmacokinetic (PK)-LDH model.[7]

Benjamin Levine et al (2019) proposed the Atrial Fibrillation (AFib) is increasingly recognized as a risk factor for clots, strokes, heart failure and other complications. One estimate states that 2.7 million individuals are living in U.S. With AFib and this number may increase to 5.6 million by 2050. Identifying patients with paroxysmal AFib early after the onset and treating them immediately may improve clinical outcomes, especially by reducing stroke. Currently AFib cases are identified only when the patients complain of palpitations or discovered during routine heart check-ups. Improving early identification warrants a simple screening device to detect the onset of AFib. We have developed a mHealth system with a wearable ECG and an automated algorithm for this purpose. The machine learning based algorithm along with patient user interface can be downloaded as an app.[8]

Yasushi Abe et al (2020) highlighted that It is well known that paroxysmal atrial fibrillation (PAF) often precedes the establishment of chronic atrial fibrillation (CAF). However, there have been no definite methods to predict the transition from PAF to CAF. The purpose of this report was to determine prospectively whether P-wave–triggered signal-averaged ECG (P-SAE) is useful for the prediction of the transition to CAF in patients with PAF.

Methods and Results One hundred twenty-two consecutive patients with PAF were prospectively followed after P-SAE, echocardiography, and 24-hour Holter monitoring at study entry. The duration (Ad) and root-mean-square voltage for the last 30 ms (LP30) of the filtered P wave were measured in P-SAE. The abnormality of P-SAE for the prediction of transition to CAF was defined as Ad ≥145 ms and LP30 <3.0 μV. Twenty-three (19%; group 1) of the patients had the abnormality of P-SAE, whereas the others (group 2) did not. During the follow-up period (mean, 26±12 months), 10 patients (43%) in group 1 acquired CAF, whereas the transition to CAF was observed in only 4 patients (4%) in group 2. Kaplan-Meier analysis revealed that the transition to CAF was significantly observed more often in group 1 than in group 2 (log-rank test, P<.0001). [9]

Koki Nakamura et al (2020) analyzed the despite technological advancements and evolving ablation strategies, atrial fibrillation catheter ablation outcome remains suboptimal for a cohort of patients. Imaging-based biomarkers have the potential to play a pivotal role in the overall assessment and prognostic stratification of AF patients, allowing for tailored treatments and individualized care. Alongside consolidated evaluation parameters, novel imaging biomarkers that can detect and stage the remodeling process and correlate it to electrophysiological phenomena are emerging. This review aims to provide a better understanding of the different types of atrial substrate, and how Computed Tomography can be used as a pre-ablation risk stratification tool by assessing the various novel imaging biomarkers, providing a valuable insight into the mechanisms that sustain AF and potentially allowing for a patient-specific ablation strategy.

Left atrium (LA) remodeling is associated with atrial fibrillation (AF) and reduced success after AF ablation, but its relation with low-voltage areas (LVA) is not known. This study aimed to evaluate the relation between regional LA changes and LVAs in AF patients.Pre-interventional CT data of patients (n = 24) with LA-LVA (<0.5 mV) in voltage mapping after AF ablation were analyzed (Surgery Explorer, QuantMD LLC). To quantify asymmetry a cutting plane parallel to the rear wall and along the pulmonary veins divided the LA-volume into anterior and posterior parts. To quantify sphericity , a patient-specific best-fit LA sphere was created. The average radius (R) and the mean deviation (S) from this sphere were calculated. The average local deviation (D) was measured for the roof, posterior, septum, inferior septum, inferior-posterior and lateral walls.The roof, posterior and septal regions had negative local deviations. There was a correlation between roof and septum , lateral and inferior-posterior as well as posterior and inferior-septal deviations . ASI correlated with septum deformation (r = −0.43, p = 0.04). LAS correlated with dilatation (LAV, r = 0.49, p = 0.02), roof (r = 0.52, p = 0.009) and posterior deformation (r = −0.56, p = 0.005). Extended LVA correlated with local deformation of all LA walls, except the roof and the septum. LVA association with LAV, ASI and LAS did not reach statistical significance. Extended LVA correlates with local wall deformations better than other remodeling surrogates. Therefore, their calculation could help predict LVA presence and deserve further evaluation in clinical studies.[10]

Yasushi Koide et al (2017) subjected the current prospective study was conducted for identifying predictors of progression to persistent AF over the long term. We studied 102 consecutive patients (mean age: 55 ± 10 years; 75 men and 27 women) diagnosed with paroxysmal AF. Standard 12-lead electrocardiography, echocardiography, and P-wave-triggered signal-averaged electrocardiography (P-SAECG) were performed on all patients at the time of their entry into the study. The mean follow-up period was 61 ± 13 months. Group 1 (n = 66) comprised patients in whom paroxysmal AF did not progress to persistent AF, and Group 2 (n = 36) comprised those who developed persistent AF. In Group 2 the patients were significantly older, and P-wave dispersion, filtered P-wave duration (FPD), and left atrial dimension were significantly higher than in Group 1 ($p < 0.05$). The root means square voltage for the last 30 ms of the filtered P-wave was also significantly lower in Group 2 ($p < 0.05$). Multivariate logistic regression analysis using these five factors identified left atrial dimension (odds ratio [OR] 2.29; 95% confidence interval [CI] 1.16-4.54; $p = 0.02$) and FPD (OR 2.71; 95% CI 1.78- 4.13; $p< 0.01$) as independent predictors of transition to persistent AF. Left atrial dimension ≤ 40 mm predicted progression to persistent AF with a sensitivity of 64%, specificity of 76%, positive predictive value of 59%, negative predictive value of 79%, and an accuracy of 71%. An FPD ≤ 150 ms predicted persistent AF with a sensitivity of 81%, specificity of 91%, positive predictive value of 88%, negative predictive value of 90%, and an accuracy of 87%. Filtered P-wave duration was a significantly more sensitive and specific predictor than left atrial dimension ($p < 0.05$).[11]

Koichi Sakabe et al (2019) presented the purpose of this study was to determine prospectively whether transthoracic echocardiography is useful for the prediction of the transition to CAF in elderly patients with nonvalvular PAF. Forty-two consecutive elderly patients (≥65 years) with nonvalvular PAF were prospectively evaluated after undergoing transthoracic echocardiography. The study endpoint was the transition to CAF (AF; ≥ 6 months). During a follow-up period of 32 ± 24 months, 12 patients developed CAF. Patients with CAF had a significantly lower peak A velocity (A) and a higher E/A ratio of the transmitral inflow (TMF) such as a pseudo normalization pattern, and a lower peak atrial reversal wave velocity, higher peak diastolic wave velocity (D), and lower peak systolic/diastolic wave velocity ratio (S/D ratio) of the pulmonary venous flow (PVF). Kaplan-Meier analysis revealed that the transition to CAF was observed more often when A was ≤ 70 cm/sec and E/A ratio was ≥ 1.07 of TMF, and D was ≥ 44 cm/sec and the S/D ratio was ≤ 1.34 of PVF. All patients developed CAF when the E/A ratio was ≥ 1.15 or the S/D ratio was ≤ 0.75. This prospective study suggests that elderly patients at high risk for transition to CAF have a pseudonormalization pattern of TMF and a diastolic dominant pattern of PVF, and that transthoracic Doppler estimation of TMF and PVF may be useful in identifying elderly patients at high risk for the transition from nonvalvular PAF to CAF.[12]

Naoto Oguri et al (2020) explained the progression from paroxysmal to persistent atrial fibrillation (AF) is occasionally encountered in patients with previous pacemaker implantation (PMI) for the treatment of tachycardia–bradycardia syndrome (TBS). We aimed to determine the rate of its incidence occurring within the early years after PMI and the predictors. We studied TBS patients who received PMI at 5 core cardiovascular canters. The end point was a conversion from paroxysmal to persistent AF. We extracted 342 TBS patients out of 2579 undergoing PMI. During 5 ± 3.1 years of follow-up, 114 (33.3%) reached the end point. The time to the end point was 2.9 ± 2.7 years. The event rates within a year and 3 years after the PMI were 8.8% and 19.6%, respectively. In the multivariate hazard analyses, hypertension (hazard ratio [HR] 3.2, $P = 0.03$) and congestive heart failure (HR 2.1, $P = 0.04$) were found to be independent predictors of the end point occurring within a year after the PMI. Congestive heart failure (HR 1.82, $P = 0.04$), left atrial diameter of ≥ 40 mm (HR 4.55, $P < 0.001$), and the use of antiarrhythmic agents (HR 0.58, $P = 0.04$) were independently associated with the 3-year end point. Prediction models including combinations of those 4 parameters for the 1- and 3-year incidence both exhibited a modest risk discrimination (both c-statistics 0.71). In conclusion, early progression from paroxysmal to persistent AF was less frequent than expected in the TBS patients with PMI. Factors related to atrial remodeling and no use of antiarrhythmic drugs may facilitate the progression.[13]

Marco Bergonti et al (2022) projected the Left atrial substrate may have mechanistic relevance for ablation of atrial fibrillation (AF). We sought to analyze the relationship between low-voltage zones (LVZs), transition zones, and AF recurrence in patients undergoing pulmonary vein isolation. We conducted a prospective multicenter study on consecutive patients undergoing pulmonary vein isolation-only approach. LVZs and transition zones (0.5–1 mV) were analyzed offline on high-density electroanatomical maps collected before pulmonary vein isolation. Overall, 262 patients (61±11 years, 31% female) with paroxysmal (130 pts) or persistent (132 pts) AF were included. After 28 months of follow-up, 73 (28%) patients experienced recurrence. An extension of more than 5% LVZ in paroxysmal AF and more than 15% in persistent AF was associated with recurrence respectively). Significant association was found between LVZs and transition zones and between LVZs and left atrial volume index (LAVI) (both $P<0.001$). Thirty percent of patients had significantly increased LAVI without LVZs. Eight percent of patients had LVZs despite normal LAVI. Older age, female sex, oncological history, and increased AF recurrence characterized the latter subgroup. In patients undergoing first pulmonary vein isolation, the impact of LVZs on outcomes occurs with lower burden in paroxysmal than persistent AF, suggesting that not all LVZs have equal prognostic implications. A proportional area of moderately decreased voltages accompanies LVZs, suggesting a continuous substrate instead of the dichotomous division of health or diseased tissue. LAVI generally correlates with LVZs, but a small subgroup of patients may present with disproportionate atrial remodeling, despite normal LAVI.[14]

Dayer Wang et al (2021) proposed the Atrial fibrillation (AF) is the most prevalent sustained arrhythmia. L1 cell adhesion molecule (L1CAM) served as a crucial regulator of signaling pathways. This research sought to examine the clinical value and functions of soluble L1CAM in the serum of AF patients. Methods: In total, 118 patients (valvular heart disease patients were recruited in this retrospective study. Plasma levels of L1CAM were detected by enzyme-linked immunosorbent assays. The Pearson's correlation approach, as applicable, was used for analyzing the correlations. The L1CAM was shown to independently serve as a risk indicator of AF in VHD after being analyzed by the multivariable logistic regression. To examine the specificity and sensitivity of AF, receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used. A nomogram was developed for the visualization of the model. We further evaluate the prediction model for AF using calibration plot and decision curve analysis.[15]

III. SYSTEM DESIGN

This chapter outlines the methods used in this project. The overview, setups, and design of this project are covered in this chapter. Besides, the hardware and software used in this project will be listed and explained. The block diagram and flowchart of the proposed system are shown in Fig.3.1 respectively.



Fig 3.1.: BLOCK DIAGRAM

A. COMPONENTS

EMG SENSOR

Electromyography (EMG) is a technique for recording biomedical electrical signals obtained from the neuromuscular activities. These signals are used to monitor medical abnormalities and activation levels, and also to analyze the biomechanics of any animal movements. In this article, we provide a short review of EMG signal acquisition and processing techniques. The average efficiency of capture of EMG signals with current technologies is around 70%. Once the signal is captured, signal processing algorithms then determine the recognition accuracy, with which signals are decoded for their corresponding purpose (e.g., moving robotic arm, speech recognition, gait analysis). The recognition accuracy can go as high as 99.8%. The accuracy with which the EMG signal is decoded has already crossed 99%, and with improvements in deep learning technology, there is a large scope for improvement in the design hardware that can efficiently capture EMG signals.

DISPOSABLE ELECTRODE

BIOPAC's disposable EL500 series electrodes offer a fast, easy, and and more hygienic alternative to reusable electrodes. EL500 series electrodes are available as pre-gelled or dry surface electrodes with snap connector with cloth, foam, long-term, paired, RT, Bioimpedance and EDA options. EL500 Series snap electrodes provide the same signal transmission as BIOPAC's reusable electrodes, with added convenience and hygiene. Each peel-and-stick disposable electrode is designed for one use only. Available pre-gelled or dry. Use disposable snap electrodes with leads from the LEAD100 series or an SS2/2L, SS29L, or SS57L lead set.

B. HARWARE AND COMMUNICATION

Node MCU: Node MCU is used as a gateway that collects the health data from the connecting sensors in this project. The gateway communicates with the broker and Arduino UNO via MQTT protocol and UART serial communication. It sends the collected data to the broker for data processing. Node MCU is used to track the user location with geolocation. With the help of geolocation, the GPS tracker is no longer needed as the geolocation function can track the location of the user through the available wifi connection surrounding the user.

C. POWER SUPPLY UNIT

Power supply is a reference to a source of electrical power. A device or system that supplies electrical or other types of energy to an output load or group of loads is called a power supply unit or PSU. The term is most commonly applied to electrical energy supplies, less often to mechanical ones, and rarely to others.
Power Adaptor 12 Volt 1 Amp Charger AC INPUT 100-240V DC OUTPUT 12V 1A.

D. SOFTWARE

RANDOM FOREST ALGORITHM

Machine learning, a fascinating blend of computer science and statistics, has witnessed incredible progress, with one standout algorithm being the Random Forest. Random forests or Random Decision Trees is a collaborative team of decision trees that work together to provide a single output. Originating in 2001 through Leo Breiman, Random Forest has become a cornerstone for machine learning enthusiasts. In this article, we will explore the fundamentals and implementation of Random Forest Algorithm.

LSTM (LONG SHORT-TERM MEMORY)

LSTMs Long Short-Term Memory is a type of RNNs Recurrent Neural Network that can detain long-term dependencies in sequential data. LSTMs are able to process and analyze sequential data, such as time series, text, and speech. They use a memory cell and gates to control the flow of information, allowing them to selectively retain or discard information as needed and thus avoid the vanishing gradient problem that plagues traditional RNNs. LSTMs are widely used in various applications such as natural language processing, speech recognition, and time series forecasting.

E. PLATFORM AND SERVICES

1) Thingsboard

Thingsboard is an open-source IoT data visualization platform. The data collected by the broker will be sent to Thingsboard via the internet for real-time visualization. Thingsboard allows users to perform real-time data monitoring through the internet.

IV. EXPERIMENTAL RESUTS

The workflow begins with the acquisition of real-time EMG bio-signals from the thighs and calves of individuals using specialized sensors or devices. These raw signals undergo pre-processing steps like noise removal and normalization to ensure data quality.Next, important features are extracted from the pre-processed data, capturing pertinent information about muscle activity patterns indicative of stroke risk. These features are then utilized to train both the Random Forest and SVM models, which learn to recognize patterns associated with stroke occurrence. The trained models are rigorously evaluated using validation data to gauge their performance metrics.





V. CONCLUSION AND FUTURE WORK

Conclusion

The conclusion of the proposed system for early stroke prediction and diagnosis through EMG technology and machine learning algorithms underscores its potential to revolutionize stroke management and improve patient outcomes. Through a comprehensive review of the system's development, methodology, results, and implications, it becomes evident that this innovative approach holds significant promise for addressing the challenges associated with stroke detection and treatment.

In conclusion, the proposed system represents a significant advancement in the field of stroke diagnosis and management. By harnessing the capabilities of EMG technology and machine learning algorithms, the system offers a cost-effective, accessible, and scalable solution for early stroke prediction and diagnosis. With further research, development, and validation, the system has the potential to transform stroke care and improve outcomes for patients worldwide.

Recommendation for Future Work

Despite the promising results, our study has several limitations that warrant consideration. Firstly, the sample size used for model training and validation may not fully capture the diversity of stroke cases and patient demographics. Future studies should aim to collect larger and more diverse datasets to enhance the generalizability of the models. Additionally, the reliance on EMG bio-signals alone may limit the predictive capabilities of the system, as stroke onset can be influenced by various physiological and environmental factors. Integrating additional sensor modalities, such as electrocardiography (ECG) or accelerometry, could improve the robustness and accuracy of the system.

VI. REFERENCES

[1]. Andrea Nathalie et.al (2020) proposed by “Long-term safety and effectiveness of

paroxysmal atrial fibrillation ablation using a porous tip contact force-sensing catheter from the SMART SF trial" *DOI: 10.1007/s10840-020-00780-4.*
[2]. Padmaloshani et.al (2020) by "Smart Paroxysm Prediction and Life Saver System".
[3]. Atrial Fibrillation et.al David Dunker (2021) "Smart Wearable for Cardiac MonitoringRealWorld Use beyond" *doi: 10.3390/s21072539.*
[4]. Yutan Gout et.al (2021) "Photoplethysmography-Based Machine Learning Approaches for Atrial FibrillationPrediction" *DOI: 10.1016/j.jacasi.2021.09.004*
[5]. Constanze Schmidt et al (2020) "Prospective multicentre validation of a novel prediction model paroxysmal atrial fibrillation" *DOI: 10.1007/s00392-020-01773-z*
[6]. Larry A Chinitz et.al (2020) "Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF" *DOI: 10.1093/europace/eux264*
[7]. panelSimon Buatois et.al (2022) "Population Pharmacokinetic/Pharmacodynamics' modelling from the Phase I/II COMPOSER Trial to Predict Lowering of Lactate Dehydrogenase in Crovalimab-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria" *DOI:10.1182/blood-2020-134590 .*
[8]. Benjamin Levine et.al (2022) "A Mobile Health System to Identify the Onset of Paroxysmal Atrial Fibrillation" *DOI: 10.1109/ICHI.2015.29.*
[9]. Yasushi Abe et.al (2020) "Prediction of Transition to Chronic Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation by Signal- Averaged Electrocardiography" *DOI: 10.1161/01.cir.96.8.2612*
[10]. Koki Nakamura et.al (2020) "Left atrial wall thickness in paroxysmal atrial fibrillation by multislice-CT is initial marker of structural remodeling and predictor of transition from paroxysmal to chronic" *https://doi.org/10.1016/j.ijcard.2009.10.032.*
[11]. Yasushi Koide et.al(2022) "Investigation of the predictors of transition to persistent atrial fibrillation in patients with paroxysmal atrial fibrillation" *DOI: 10.1002/clc.4950250206*
[12]. Koichi Sakabe et.al(08/oct/2020) "Prediction of Transition to Chronic Atrial Fibrillation in Elderly Patients with Nonvalvular Paroxysmal Atrial Fibrillation by Transthoracic Doppler Echocardiography" *doi: 10.1002/clc.20489*
[13]. Naoto Oguri (2022) "Progression from paroxysmal to persistent atrial fibrillation in pacemaker patients with tachycardia–bradycardia syndrome" *DOI: 10.1007/s00380-023-02266-5.*
[14]. Marco Bergonti et.al (2022) "Characterization of Atrial Substrate to Predict the Success of Pulmonary Vein Isolation: The Prospective, Multicenter MASH-AF II (Multipolar Atrial Substrate High Density Mapping in Atrial Fibrillation" *DOI: 10.1161/JAHA.122.027795*
[15]. Dayer Wang et.al (2019) "cell adhesion molecule may be a protective molecule for atrial fibrillation in patients with valvular heart disease" *DOI: 10.1016/j.heliyon.2023.e16831.*